Academy of Neurology (AAN) 2023 Annual Meeting, Amneal presented new data evaluating IPX203 (carbidopa + levodopa, CD/LD) in a nine-month open-label extension (OLE) study in Parkinson’s disease (PD) patients with motor fluctuations (NCT03877510). The OLE study involved 419 participants who completed the Phase III RISE-PD (NCT03670953). This data highlights that IPX203 could offer an additional safe and tolerable extended-release formulation of CD/LD and could offer an overall better quality of life in moderate to advanced-stage PD patients. IPX203 is currently under review by the FDA for the treatment of PD, with a PDUFA date of 30 June 2023.
AAN 2023: Amneal’s IPX203 shows promise f... - Cure Parkinson's
AAN 2023: Amneal’s IPX203 shows promise for Parkinson’s disease patients
Written by
Farooqji
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
Electroconvulsive Therapy Intervention for Parkinson’s Disease
Have not heard of this option before: Electroconvulsive Therapy Intervention for Parkinson’s...
Patients with Parkinson’s disease (PD) report a strong craving for sweets
"Lately, studies have shown that patients with Parkinson’s disease (PD) report a strong craving...
Mucuna pruriens in Parkinson’s
Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study
R...
Mucuna Pruriens in Parkinson's disease, dosages and effects, A double-blind, randomized, controlled, crossover human study (2017)
Mucuna pruriens in Parkinson disease. A double-blind, randomized, controlled, crossover study...
Seafood shows promise as a future Parkinson's disease medication
Perhaps as a future PD medication, but nothing prevents you from enjoying seafood in your (MIND)...